Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
BACKGROUND: The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib.
METHOD: A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression.
RESULTS: One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival.
CONCLUSION: Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:121 |
|---|---|
| Enthalten in: |
British journal of cancer - 121(2019), 7 vom: 02. Okt., Seite 537-544 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Solis-Hernandez, Mª Pilar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 20.05.2020 Date Revised 11.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41416-019-0558-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300869894 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300869894 | ||
| 003 | DE-627 | ||
| 005 | 20231225103438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-019-0558-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1002.xml |
| 035 | |a (DE-627)NLM300869894 | ||
| 035 | |a (NLM)31477779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Solis-Hernandez, Mª Pilar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib |b comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2020 | ||
| 500 | |a Date Revised 11.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib | ||
| 520 | |a METHOD: A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression | ||
| 520 | |a RESULTS: One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival | ||
| 520 | |a CONCLUSION: Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Sunitinib |2 NLM | |
| 650 | 7 | |a V99T50803M |2 NLM | |
| 700 | 1 | |a Fernandez Del Valle, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona-Bayonas, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Carbonero, Rocio |e verfasserin |4 aut | |
| 700 | 1 | |a Custodio, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Benavent, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso Gordoa, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Nuñez-Valdovino, Bárbara |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez Canovas, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Matos, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Viudez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Izquierdo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo-Temprano, David |e verfasserin |4 aut | |
| 700 | 1 | |a Grande, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Capdevila, Jaume |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Fonseca, Paula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 121(2019), 7 vom: 02. Okt., Seite 537-544 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:121 |g year:2019 |g number:7 |g day:02 |g month:10 |g pages:537-544 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-019-0558-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 121 |j 2019 |e 7 |b 02 |c 10 |h 537-544 | ||